Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03034772 · ClinicalTrials.gov registry record · Phase 2
Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
A Phase 2 study, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT03034772 is a Phase 2 study that has completed, run by Wills Eye. The registered enrollment target is 52 participants.
The verdict
NCT03034772, a Phase 2 study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
A previous pilot study demonstrated that commonly available glaucoma drops (dorzolamide-timolol) might decrease the amount of chronic swelling in patient with wet age-related macular degeneration who have been receiving anti-vascular endothelial growth factor (VEGF) injections. This will be a larger study where subjects are randomly assigned to receive the glaucoma drops or a placebo (artificial tears) in order to confirm whether this previous finding is valid. Subjects will continue to receive the normally scheduled anti-VEGF injections at regular intervals as done prior to enrollment. The only addition to the regimen will be the daily use of eye drops (dorzolamide-timolol or artificial tears) twice daily for the duration of the study. At the end of the study, the swelling in the retina will be compared to the amount before starting the drops to see if there is any difference between the group using dorzolamide-timolol versus artificial tears.
Interventions
- OTHER Artificial tears
- DRUG Dorzolamide-timolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-02-08 |
| Est. Completion | 2019-07-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03034772
The ClinicalTrials.gov registry entry for NCT03034772 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Artificial tears is the first listed.
NCT03034772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03034772 about?
NCT03034772 is a clinical study titled "Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration". A previous pilot study demonstrated that commonly available glaucoma drops (dorzolamide-timolol) might decrease the amount of chronic swelling in patient with wet age-related macular degeneration who have been receiving anti-vascular endothelial growth factor (VEGF) injections. This will be a larger...
What is the current status of trial NCT03034772?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2017-02-08. Estimated completion is 2019-07-05.
What interventions are being tested in trial NCT03034772?
The interventions under investigation include: Artificial tears (OTHER), Dorzolamide-timolol (DRUG).
Who is sponsoring clinical trial NCT03034772?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.